DBV Technologies S.A. (DBV.PA)
EUR 0.61
(1.17%)
EUR 0.61
(1.17%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -114.95 Million USD | 42.28% |
| 2022 | -199.17 Million USD | -239.84% |
| 2021 | -58.6 Million USD | 64.09% |
| 2020 | -163.22 Million EUR | 1.12% |
| 2019 | -165.06 Million EUR | -21.33% |
| 2018 | -136.05 Million EUR | 14.92% |
| 2017 | -159.9 Million EUR | 39.59% |
| 2016 | -264.69 Million EUR | 23.95% |
| 2015 | -348.04 Million EUR | -159.39% |
| 2014 | -134.17 Million EUR | -156.33% |
| 2013 | -52.34 Million EUR | -6.61% |
| 2012 | -49.1 Million EUR | -253.67% |
| 2011 | -13.88 Million EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -58.62 Million EUR | 33.15% |
| 2024 Q1 | -94.28 Million USD | 30.06% |
| 2023 Q2 | -171.39 Million USD | 9.5% |
| 2023 Q1 | -189.38 Million USD | 4.91% |
| 2023 FY | -114.95 Million USD | 42.28% |
| 2023 Q4 | -134.81 Million USD | 8.2% |
| 2023 Q3 | -146.84 Million USD | 14.32% |
| 2022 FY | -199.17 Million USD | -239.84% |
| 2022 Q4 | -199.17 Million USD | 4.81% |
| 2022 Q1 | -68.67 Million USD | -17.18% |
| 2022 Q2 | -242.67 Million USD | -253.34% |
| 2022 Q3 | -209.23 Million USD | 13.78% |
| 2021 Q2 | -111.8 Million USD | 13.24% |
| 2021 Q1 | -128.85 Million USD | 21.05% |
| 2021 Q3 | -85.07 Million USD | 23.91% |
| 2021 Q4 | -58.6 Million USD | 31.11% |
| 2021 FY | -58.6 Million USD | 64.09% |
| 2020 Q4 | -163.22 Million EUR | 0.0% |
| 2020 Q2 | -228.65 Million EUR | 0.0% |
| 2020 FY | -163.22 Million EUR | 1.12% |
| 2019 Q4 | -165.06 Million EUR | -218.31% |
| 2019 Q2 | -92.36 Million EUR | 0.0% |
| 2019 Q3 | -51.85 Million EUR | 43.86% |
| 2019 FY | -165.06 Million EUR | -21.33% |
| 2018 FY | -136.05 Million EUR | 14.92% |
| 2018 Q4 | -136.05 Million EUR | 0.0% |
| 2018 Q2 | -229.67 Million EUR | 0.0% |
| 2017 Q2 | -222.17 Million EUR | 0.0% |
| 2017 Q4 | -159.9 Million EUR | 0.0% |
| 2017 FY | -159.9 Million EUR | 39.59% |
| 2016 Q4 | -264.69 Million EUR | 0.0% |
| 2016 FY | -264.69 Million EUR | 23.95% |
| 2016 Q2 | -315.83 Million EUR | 0.0% |
| 2015 Q4 | -348.04 Million EUR | 0.0% |
| 2015 Q2 | -111.49 Million EUR | 0.0% |
| 2015 FY | -348.04 Million EUR | -159.39% |
| 2014 Q2 | -37.28 Million EUR | 0.0% |
| 2014 Q4 | -134.17 Million EUR | 0.0% |
| 2014 FY | -134.17 Million EUR | -156.33% |
| 2013 FY | -52.34 Million EUR | -6.61% |
| 2013 Q4 | -52.34 Million EUR | 0.0% |
| 2013 Q2 | -39.92 Million EUR | 0.0% |
| 2012 Q4 | -49.1 Million EUR | 0.0% |
| 2012 FY | -49.1 Million EUR | -253.67% |
| 2012 Q2 | -52.56 Million EUR | 0.0% |
| 2011 Q4 | -13.88 Million EUR | 0.0% |
| 2011 FY | -13.88 Million EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | -714 Thousand EUR | -16000.262% |
| ABIVAX Société Anonyme | -196.47 Million EUR | 41.492% |
| Adocia SA | 127 Thousand EUR | 90616.431% |
| Aelis Farma SA | -16.19 Million EUR | -609.955% |
| Biophytis S.A. | 2.7 Million EUR | 4352.899% |
| Advicenne S.A. | 12.17 Million EUR | 1044.196% |
| genOway Société anonyme | 2.97 Million EUR | 3966.703% |
| IntegraGen SA | -709.74 Thousand EUR | -16096.693% |
| Medesis Pharma S.A. | 1.15 Million EUR | 10025.304% |
| Neovacs S.A. | -237.08 Thousand EUR | -48386.787% |
| NFL Biosciences SA | -2.27 Million EUR | -4951.074% |
| Plant Advanced Technologies SA | 4.35 Million EUR | 2738.715% |
| Quantum Genomics Société Anonyme | -830.54 Thousand EUR | -13740.966% |
| Sensorion SA | 1.37 Million EUR | 8440.882% |
| Theranexus Société Anonyme | 2.44 Million EUR | 4803.297% |
| TME Pharma N.V. | -1.07 Million EUR | -10553.927% |
| Valbiotis SA | -18.13 Million EUR | -533.75% |
| TheraVet SA | 12.78 Thousand EUR | 899246.406% |
| Valerio Therapeutics Société anonyme | 2.18 Million EUR | 5373.205% |
| argenx SE | -1.83 Billion EUR | 93.741% |
| BioSenic S.A. | 28.04 Million EUR | 509.913% |
| Celyad Oncology SA | -6.1 Million EUR | -1783.905% |
| Galapagos NV | -157.2 Million EUR | 26.876% |
| Genfit S.A. | -7.61 Million EUR | -1410.391% |
| GeNeuro SA | 5.91 Million EUR | 2044.976% |
| Hyloris Pharmaceuticals SA | -25.11 Million EUR | -357.773% |
| Innate Pharma S.A. | -30.71 Million EUR | -274.303% |
| Inventiva S.A. | 10.48 Million EUR | 1195.966% |
| MaaT Pharma SA | -10.2 Million EUR | -1026.466% |
| MedinCell S.A. | 39.5 Million EUR | 391.02% |
| Nanobiotix S.A. | -24.71 Million EUR | -365.069% |
| Onward Medical N.V. | -12.89 Million EUR | -791.545% |
| Oryzon Genomics S.A. | 1.43 Million EUR | 8136.995% |
| OSE Immunotherapeutics SA | 27.12 Million EUR | 523.738% |
| Oxurion NV | 10.71 Million EUR | 1173.351% |
| Pharming Group N.V. | 99.4 Million EUR | 215.648% |
| Poxel S.A. | 44.55 Million EUR | 357.986% |
| GenSight Biologics S.A. | 16.29 Million EUR | 805.51% |
| Transgene SA | -14.4 Million EUR | -697.806% |
| Financière de Tubize SA | 78.62 Million EUR | 246.207% |
| UCB SA | 2.17 Billion EUR | 105.28% |
| Valneva SE | 82.73 Million EUR | 238.943% |
| Vivoryon Therapeutics N.V. | -18.52 Million EUR | -520.578% |